fluorodeoxyuridine

Small moleculeexperimental

Floxuridine is an oncology drug that belongs to the class known as antimetabolites. Specifically, floxuridine is a pyrimidine analog, classified as a deoxyuridine. The drug is usually administered via an artery, and most often used in the treatment of colorectal cancer. The quality of life and survival rates of individuals that receive continuous hepatic artery infusion of floxuridine for colorectal cancer metastases is significantly higher than control groups. Floxuridine can also be prescribed for the treatment of kidney and stomach cancers. In vitro uses of floxuridine include 5-minute treatments of fluorouracil, floxuridine, and mitomycin to increase cell proliferation in Tenon's capsule fibroblasts. — Wikipedia

Clinical trial activity

2 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Sep 1, 1995 (NCT00001449)

Timeline

1990s

  1. Jan 1, 1995

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • fluorodeoxyuridine
  • fluorodeoxyuridine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02402972Phase 3Feb 1, 2015Baylor University, Fudan University, Harbin Medical University, Jiao Tong University, Zhejiang University
NCT00001449Phase 1Sep 1, 1995National Cancer Institute (NCI)
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Baylor UniversityAcademic/Hospital1112015
Fudan UniversityAcademic/Hospital1012015
Harbin Medical UniversityAcademic/Hospital1012015
Jiao Tong UniversityAcademic/Hospital1012015
National Cancer Institute (NCI)Government1111995
Zhejiang UniversityAcademic/Hospital1012015
6 organizations
Page 1 / 1